Myosin from the ventricle is more sensitive to omecamtiv mecarbil than myosin from the atrium

Biochem Biophys Res Commun. 2020 Aug 6;528(4):658-663. doi: 10.1016/j.bbrc.2020.05.108. Epub 2020 Jun 6.

Abstract

Omecamtiv mecarbil (OM), an activator of cardiac myosin, strongly affects contractile characteristics of the ventricles and, to a much lesser extent, the characteristics of atrial contraction. We compared the molecular mechanism of action of OM on the interaction of atrial and ventricular myosin with actin using an optical trap and an in vitro motility assay. In concentrations up to 0.5 μM, OM did not affect the step size of a myosin molecule but reduced it at a higher OM level. OM substantially prolonged the interaction of both isoforms of myosin with actin. However, the interaction characteristics of ventricular myosin with actin were more sensitive to OM than those of atrial myosin. Our results, obtained at the level of isolated proteins, can explain why the impact of OM in therapeutic concentrations on the contractile function of the atrium is less significant as compared to those of the ventricle.

Keywords: Actin-myosin interaction; Atrial and ventricular myosin; In vitro motility assay; Omecamtiv mecarbil; Optical trap.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Animals
  • Heart Atria / drug effects*
  • Heart Atria / metabolism
  • Heart Ventricles / drug effects*
  • Heart Ventricles / metabolism
  • Myocardial Contraction / drug effects
  • Myosins / metabolism*
  • Protein Interaction Maps / drug effects
  • Swine
  • Urea / analogs & derivatives*
  • Urea / pharmacology

Substances

  • Actins
  • omecamtiv mecarbil
  • Urea
  • Myosins